ADM (NYSE: ADM), a global leader in innovative solutions from nature, today announced that spore-forming probiotic DE111™* (Bacillus subtilis) has received official approval from the Therapeutic Goods Administration (TGA), a part of the Australian Department of Health. This extends DE111™’s availability into new regions**, following the recent approval from the National Health Commission (NHC) in China.
“This is an important milestone for ADM, as it marks the first Bacillus subtilis strain to be approved by the TGA in Australia,” said Helen Hu, president of health & wellness APAC at ADM. “By expanding access to DE111™, we’re facilitating new innovation possibilities for our Australian customers, enabling the development of pioneering gut health-supporting products. Additionally, the continued approval of DE111 ™ by important government authorities demonstrates its high quality, safety and alignment with strict regulatory standards.”
Clinically documented results show that DE111™:
- Supports digestive health1 and helps support healthy immune function2,3.
- Can survive through the stomach and germinate in the small intestine4.
- Can support a healthy gastrointestinal (GI) tract, gut function, and microbiome diversity.
“DE111 ™ is a spore-forming probiotic, which means it can withstand harsh formulation environments that may otherwise damage conventional probiotics. This robustness is paving the way for new, convenient, and enjoyable foods, beverages, and dietary supplements that meet people where they are on their wellness journeys, especially as more consumers make the connection between their gut and digestive health and other aspects of well-being,” continued Hu.
In Australia, 81 percent of consumers recognize a link between digestive health and overall well-being, and 76 percent specifically see a connection between their digestive health and immune function5. Plus, 64 percent of Australian consumers state that they have used probiotics/cultures to address digestive health concerns over the past 12 months5. Simultaneously, the Australian probiotic supplement market is anticipated to grow, with Euromonitor reporting a forecasted CAGR of 2.7 percent between 2023 and 20286.
For more information about DE111 ™ and ADM’s microbiome solutions library, please visit www.adm.com/en-us/products-services/human-nutrition/products/microbiome-solutions/.
*DE111® is a trademark of Deerland Probiotics & Enzymes, Inc. in the US and other countries.
**Local regulations must be reviewed to confirm the permissibility of ingredients for each food category.
1Labellarte, G., et al. (2019) Food and Nutrition Sciences, 10, 626-634
2Freedman, K.E., et al. (2021) Int. J. Mol. Sci. 2021, 22, 2453
3Townsend, J., et al. (2018) Sports, 6(3), 70
4Colom J.; et al. (2021) Front. Microbiol., 12:715863
5FMCG Gurus, Digestive Health Global Study, 2022
6Euromonitor Passport Data, Retail RSP Values, USD Millions, Fixed 2023 ex Rates, Constant 2023 Prices
About ADM
ADM unlocks the power of nature to enrich the quality of life. We’re an essential global agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. We’re a premier human and animal nutrition provider, offering one of the industry’s broadest portfolios of ingredients and solutions from nature. We’re a trailblazer in health and well-being, with an industry-leading range of products for consumers looking for new ways to live healthier lives. We’re a cutting-edge innovator, guiding the way to a future of new consumer and industrial solutions. And we’re a leader in sustainability, scaling across entire value chains to help decarbonize the multiple industries we serve. Around the globe, our innovation and expertise meet critical needs while nourishing quality of life and supporting a healthier planet. Learn more at www.adm.com.
